Last reviewed · How we verify
VDPHL01 QD
VDPHL01 QD is a small molecule that targets the H3 histone deacetylase (HDAC) to modulate gene expression.
VDPHL01 QD is a small molecule that targets the H3 histone deacetylase (HDAC) to modulate gene expression. Used for Moderate to severe plaque psoriasis.
At a glance
| Generic name | VDPHL01 QD |
|---|---|
| Sponsor | Veradermics, Inc. |
| Drug class | HDAC inhibitor |
| Target | H3 histone deacetylase (HDAC) |
| Modality | Small molecule |
| Therapeutic area | Inflammatory diseases |
| Phase | Phase 3 |
Mechanism of action
By inhibiting HDAC, VDPHL01 QD aims to reduce inflammation and modulate the immune response. This mechanism is thought to be beneficial in treating various inflammatory conditions.
Approved indications
- Moderate to severe plaque psoriasis
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Safety and Efficacy of VDPHL01 in Males With AGA (PHASE3)
- Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) (PHASE3)
- Efficacy and Safety of VDPHL01 in Males With AGA (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |